In his statement on behalf of BIO regarding 21st Century Cures Initiative discussion draft, Jim Greenwood lauded such aspects as prioritization of placing patients at center of drug development process; secure and transparent framework for incorporating patient views into development/regulatory review processes; and modernization of clinical trials. Greenwood also commented on FDA recognition as well as enhancing FDA's scientific capacity on multiple fronts.